Clinical Trial

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics, Activity and Immunogenicity of HS-10370 in Combination With Other Anti-cancer Therapies in Chinese patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in and Colorectal cancer(CRC) and non-Small cell lung cancer (NSCLC).
Trial Details
NCT Number NCT06963502
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer
Enrollment 762 participants
Start Date 2025-05-30
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-09